Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Olaparib improves progression free survival up front in ovarian cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 21.10.18
Views: 800

Dr Kathleen N. Moore - The Stephenson Cancer Center, Oklahoma City, USA

Dr Kathleen N. Moore presented data at the ESMO 2018 congress in Munich from the SOLO1 trial of maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients with advanced ovarian cancer and BRCA1/2 mutation.

For more on these results, watch her interview with ecancer here.

Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation